A New Direction in Endometrial Cancer Therapy-PD-1 and PD-L1 Immune Checkpoint Inhibitors-Where Will It Take Us?

Natalia Mielnicka, Martyna Dutka, Krzysztof Kułak, Anna Kułak, Rafał Tarkowski

Abstract readReview

In one paragraph

Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Natalia MielnickaStudent's Scientific Association, I Chair and Department and Clinic of Oncological Gynecology and Gynecology, Medical University of Lublin, 16 Staszica St., 20-081 Lublin, Poland.ORCID 0009-0005-3648-6529

Martyna DutkaStudent's Scientific Association, I Chair and Department and Clinic of Oncological Gynecology and Gynecology, Medical University of Lublin, 16 Staszica St., 20-081 Lublin, Poland.ORCID 0009-0006-4747-677X

Krzysztof KułakI Chair and Department and Clinic of Oncological Gynecology and Gynecology, Medical University of Lublin, 16 Staszica St., 20-081 Lublin, Poland.ORCID 0000-0001-9059-484X

Anna KułakDepartment of Diagnostic and Microsurgery of Glaucoma, Medical University of Lublin, 1 Chmielna St., 20-079 Lublin, Poland.

Rafał TarkowskiI Chair and Department and Clinic of Oncological Gynecology and Gynecology, Medical University of Lublin, 16 Staszica St., 20-081 Lublin, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atezolizumabdostarlimabendometrial cancerimmune checkpoint inhibitorspembrolizumab

Identifiers

PMID41375669

DOI10.3390/jcm14238366

PMCPMC12693102

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.